Sanofi, Facing Threat from Generics, Moves to Buy Hemophilia Drug Maker

The $11.6 billion deal for Bioverativ would bolster the French pharmaceutical giant’s portfolio as it faces falling sales for its diabetes drug, Lantus.

from NYT > Health http://ift.tt/2n1BDDI
via health&fitness